ImmunityBio, Inc. (IBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.08-1.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IBRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | 165.8 | 113.3 | 14.7 | 0.6 | 0.2 | 0.9 | 0.6 | 2.2 | 0.0 | 0.0 | 0.0 | 0.2 |
| Total Revenues | 165.8 | 113.3 | 14.7 | 0.6 | 0.2 | 0.9 | 0.6 | 2.2 | 0.0 | 0.0 | 0.0 | 0.2 |
| Cost of Revenues | 1.1 | 0.8 | — | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||
| Selling, General & Admin | — | — | 168.8 | 129.6 | 102.7 | 135.3 | 71.3 | 46.5 | 42.7 | 57.1 | 95.4 | 227.7 |
| R&D Expenses | — | — | 190.1 | 232.4 | 248.1 | 196.0 | 139.5 | 112.0 | 55.7 | 42.0 | 29.2 | 11.4 |
| Operating Income | (251.8) | (256.0) | (344.2) | (362.3) | (351.3) | (330.3) | (220.9) | (156.3) | (98.4) | (99.1) | (124.5) | — |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | — | 60.9 | 114.7 | 128.8 | 63.5 | 14.8 | 9.1 | — | — | 0.6 | 0.1 | 0.5 |
| Interest & Investment Income | — | — | — | — | — | — | 1.7 | 2.8 | 2.3 | 4.2 | 5.2 | 0.3 |
| Net Interest Expenses | — | — | — | — | — | — | 7.3 | — | — | (3.6) | (5.1) | 0.2 |
| Other Non-Operating Income / Expenses | (740.8) | (95.6) | (69.5) | (221.6) | (66.0) | (19.6) | (5.2) | (4.0) | 1.7 | 2.2 | 3.1 | — |
| Asset Writedown | — | — | — | — | — | — | 0.0 | 0.9 | — | — | — | — |
| EBT, Incl. Unusual Items | (992.6) | (351.6) | (413.6) | (583.9) | (417.3) | (349.8) | (226.0) | (160.3) | (96.7) | (96.9) | (121.4) | — |
| Income Tax Expense | — | (0.1) | — | (0.0) | 0.0 | 0.0 | (1.8) | (0.1) | (0.5) | (0.5) | (0.6) | (0.3) |
| Earnings from Continuing Operations | — | — | — | — | — | — | (221.9) | — | — | — | — | — |
| Net Income | ||||||||||||
| Minority Interest | (0.1) | (0.1) | (0.1) | (0.7) | (0.8) | (3.1) | (2.3) | — | — | — | — | — |
| Net Income | (992.5) | (351.4) | (413.6) | (583.9) | (417.3) | (349.8) | (221.9) | (157.8) | (96.2) | (96.4) | (120.8) | (236.9) |
| Per Share | ||||||||||||
| Basic EPS | (0.95) | (0.38) | (0.59) | (1.15) | (1.04) | (0.89) | (0.59) | — | — | — | — | — |
| Diluted EPS | (0.95) | (0.38) | (0.62) | (1.15) | (1.04) | (0.89) | (0.59) | — | — | — | — | — |
| Revenue per Share | 0.16 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 1,050.1 | 919.9 | 697.3 | 508.6 | 399.9 | 389.2 | 377.1 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 1,050.1 | 919.9 | 700.4 | 508.6 | 399.9 | 389.2 | 377.1 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | (240.5) | (326.6) | (343.7) | (333.0) | (316.0) | (208.1) | (142.2) | (88.8) | (93.6) | (120.9) | — |
| EBIT | (251.8) | (256.0) | (344.2) | (362.3) | (351.3) | (330.3) | (220.9) | (156.3) | (98.4) | (99.1) | (124.5) | — |
| Effective Tax Rate | — | — | — | 0.0% | -0.0% | -0.0% | 0.8% | 0.1% | 0.5% | 0.5% | 0.5% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.